The primary genetic susceptibility factors in LCH involve gain-of-function mutations in the mitogen-activated protein kinase (MAPK) signaling pathway, notably the BRAF V600E and MAP2K1 mutations [12]. Here, MAP2K1 is linked to Langerhans cell histiocytosis.